<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40796840</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1746-6148</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC veterinary research</Title><ISOAbbreviation>BMC Vet Res</ISOAbbreviation></Journal><ArticleTitle>Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.</ArticleTitle><Pagination><StartPage>512</StartPage><MedlinePgn>512</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12917-025-04962-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sodium-glucose cotransporter 2 inhibitors are widely used in human medicine for their insulin-independent glucose-lowering effects. However, their clinical efficacy and safety for managing diabetes mellitus in dogs have not been established. This study aimed to evaluate the efficacy and safety of DWP16001, a selective sodium-glucose cotransporter 2 inhibitor, as an adjunct to insulin therapy for client-owned dogs with diabetes mellitus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, randomized, double-blind, placebo-controlled clinical trial involved 61 dogs receiving stable insulin therapy. They were randomly assigned to receive DWP16001 (0.025&#xa0;mg/kg PO q24h) or placebo for 8 weeks. The changes in the serum fructosamine (weeks 0, 1, 4, and 8) and HbA1c (weeks 0, 4 and 8) concentrations and daily insulin dose were assessed. Safety evaluations included adverse event monitoring, physical examination, body weight measurement, blood gas and ketone analyses, urinalysis, and hematologic and biochemical profiling. Hypoglycemia was detected via blood glucose curve.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DWP16001 significantly reduced fructosamine and HbA1c concentrations in the dogs, especially in those with poor baseline glycemic control (fructosamine&#x2009;&#x2265;&#x2009;500 &#xb5;mol/L, HbA1c&#x2009;&#x2265;&#x2009;6%). A trend toward reduced insulin requirements was observed in the treatment group without significant weight loss or clinically relevant changes in systolic blood pressure or signs of volume depletion. Asymptomatic hypoglycemia was detected in four dogs receiving DWP16001, but it resolved following insulin dose adjustment. No episodes of diabetic ketoacidosis were recorded, and laboratory parameters remained stable throughout the study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DWP16001 is a safe and effective adjunct to insulin therapy for diabetic dogs, especially those with suboptimal glycemic control. It demonstrated insulin-sparing effects and favorable metabolic safety, necessitating further evaluation in long-term clinical studies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>An</LastName><ForeName>Ju-Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Veterinary Emergency and Critical Care Medicine, Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Byung-Gee</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namkung</LastName><ForeName>Hyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hye-Gyu</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Hyun-Woo</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Global Business Center, Daewong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huh</LastName><ForeName>Wan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Global Business Center, Daewong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joon Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Daewoong Pharmaceutical, Life Science Institute, Yongin, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Jae-Bong</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Daewoong pet, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Hwa-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Min-Ok</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Laboratory of Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea. apple963@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No grant ID</GrantID><Agency>The Research Institute for Veterinary Science, Seoul National University.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D000081262">Randomized Controlled Trial, Veterinary</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Vet Res</MedlineTA><NlmUniqueID>101249759</NlmUniqueID><ISSNLinking>1746-6148</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000729921">Enavogliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>4429-04-3</RegistryNumber><NameOfSubstance UI="D019270">Fructosamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004283" MajorTopicYN="Y">Dog Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019270" MajorTopicYN="N">Fructosamine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001572" MajorTopicYN="N" AutoHM="Y">Benzofurans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DWP16001</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Dogs</Keyword><Keyword MajorTopicYN="N">Sodium-glucose cotransporter-2 inhibitor</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ARRIVE guidelines, institutional animal welfare regulations, and the principles of the Guide for the Care and Use of Laboratory Animals. The study protocol was approved by the Institutional Animal Care and Use Committee (DWP-IACUC-007), and written informed consent was obtained from all owners. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40796840</ArticleId><ArticleId IdType="pmc">PMC12341280</ArticleId><ArticleId IdType="doi">10.1186/s12917-025-04962-y</ArticleId><ArticleId IdType="pii">10.1186/s12917-025-04962-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter Inhibition in the management of type 2 diabetes mellitus. Am J Physiol-Renal Physiol. 2015;309(11):F889-900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4669360</ArticleId><ArticleId IdType="pubmed">26354881</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27941935</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394798</ArticleId><ArticleId IdType="pubmed">30701480</ArticleId></ArticleIdList></Reference><Reference><Citation>Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabet Vasc Dis Res. 2012;9(2):117&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">22381403</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">30132034</ArticleId></ArticleIdList></Reference><Reference><Citation>Rand JS, Fleeman LM, Farrow HA, Appleton DJ, Lederer R. Canine and feline diabetes mellitus: nature or nurture? J Nutr. 2004;134(8):S2072&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">15284406</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri K, Ganguly S, Praveen PK, Wakchaure R. Diabetes mellitus in dogs and its associated complications: a review. Int J Rec Biotech. 2015;3(4):18&#x2013;22.</Citation></Reference><Reference><Citation>Kim B, Huh KY, Hwang JG, Nah J, Huh W, Cho JM, Jang IJ, Yu KS, Kim Y, Lee S. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium&#x2013;glucose cotransporter 2 inhibitor and Metformin in healthy subjects. Br J Clin Pharmacol. 2023;89(4):1462&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">36422809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Bae SH, Jeon S, Ji HY, Han S. Combined translational pharmacometrics approach to support the design and conduct of the first-in&#x2010;human study of DWP16001. Br J Clin Pharmacol. 2024;90(1):286&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">37602795</ArticleId></ArticleIdList></Reference><Reference><Citation>An JH, Choi HS, Choi JS, Lim HW, Huh W, Oh YI, Park JS, Han J, Lim S, Lim CY. Effect of the sodium-glucose cotransporter&#x2010;2 inhibitor, DWP16001, as an add&#x2010;on therapy to insulin for diabetic dogs: a pilot study. Veterinary Med Sci. 2024;10(3):e1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11058604</ArticleId><ArticleId IdType="pubmed">38686463</ArticleId></ArticleIdList></Reference><Reference><Citation>Box JR, Oyama MA, Mosenco AS, Hess RS. Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin&#x2010;treated diabetic dogs. J Vet Intern Med. 2024;38(3):1353&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11099740</ArticleId><ArticleId IdType="pubmed">38528660</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrend EN, Ward CR, Chukwu V, Cook AK, Kroh C, Lathan P, May J, Schermerhorn T, Scott-Moncrieff JC, Voth R. Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. J Am Vet Med Assoc. 2024;1(aop):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">39142336</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedict SL, Mahony OM, McKee TS, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus. Can J Vet Res. 2022;86(1):52&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8697324</ArticleId><ArticleId IdType="pubmed">34975223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Fan F, Wang J, Long Y, Gao C, Stanton R, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7(1):44128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343472</ArticleId><ArticleId IdType="pubmed">28276512</ArticleId></ArticleIdList></Reference><Reference><Citation>Datte K, Guillaumin J, Barrett S, Monnig A, Cooper E. Retrospective evaluation of the use of glucagon infusion as adjunctive therapy for hypoglycemia in dogs: 9 cases (2005&#x2013;2014). J Vet Emerg Crit Care. 2016;26(6):775&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">27541206</ArticleId></ArticleIdList></Reference><Reference><Citation>Maffei P, Bettini S, Busetto L, Dassie F. SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations. Diabet Metabol Syndr Obes. 2023. 10.2147/DMSO.S240903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10642354</ArticleId><ArticleId IdType="pubmed">37964939</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Baldo F, Magna L, Dondi F, Maramieri P, Catrina OM, Corradini S, Linari G, Golinelli S, Tardo AM, Bonfanti U. Comparison of serum fructosamine and glycated hemoglobin values for assessment of glycemic control in dogs with diabetes mellitus. Am J Vet Res. 2020;81(3):233&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">32101039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N-Y, An J, Jeong J-K, Ji S, Hwang S-H, Lee H-S, Kim M-C, Kim H-W, Won S, Kim Y. Evaluation of a human glycated hemoglobin test in canine diabetes mellitus. J Vet Diagn Invest. 2019;31(3):408&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838714</ArticleId><ArticleId IdType="pubmed">30776981</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022;11(3):927&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9051698</ArticleId><ArticleId IdType="pubmed">35495849</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(11):841&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11471837</ArticleId><ArticleId IdType="pubmed">39017631</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HJ, Stef&#xe1;nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JF, McMurray JJ, Lindberg M, Rossing P. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>Niessen SJ, Bjornvad C, Church DB, Davison L, Esteban-Saltiveri D, Fleeman LM, Forcada Y, Fracassi F, Gilor C, Hanson J. Agreeing Language in veterinary endocrinology (ALIVE): diabetes mellitus-a modified Delphi-method-based system to create consensus disease definitions. Vet J. 2022;289:105910.</Citation><ArticleIdList><ArticleId IdType="pubmed">36182064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>